Preclinical Evaluation of 68 Ga- and 177 Lu-Labeled Integrin α v β 6 -Targeting Radiotheranostic Peptides
Journal of Nuclear Medicine · 2023-04 · 64 (4) · 639-644
DOI: 10.2967/jnumed.122.264749 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 07.10.2022. Verfasst von Tanushree Ganguly und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, University of California Davis, Davis, California. Hauptthemen laut MEDLINE: Gallium Radioisotopes, Positron Emission Tomography Computed Tomography. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
The integrin αvβ6, an epithelium-specific cell surface receptor, is overexpressed on numerous malignancies, including the highly lethal pancreatic ductal adenocarcinomas. Here, we developed and tested a novel αvβ6-targeting peptide, DOTA-5G (1) radiolabeled with 68Ga, for PET/CT imaging and 177Lu for treatment. With the goal to develop a radiotheranostic, further modifications were made for increased circulation time, renal recycling, and tumor uptake, yielding DOTA-albumin-binding moiety-5G (2).
Methods
Peptides 1 and 2 were synthesized on solid phase, and their affinity for αvβ6 was assessed by enzyme-linked immunosorbent assay. The peptides were radiolabeled with 68Ga and 177Lu. In vitro cell binding, internalization, and efflux of 68Ga-1 and 177Lu-2 were evaluated in αvβ6-positive BxPC-3 human pancreatic cancer cells. PET/CT imaging of 68Ga-1 and 68Ga-2 was performed on female nu/nu mice bearing subcutaneous BxPC-3 tumors. Biodistribution was performed for 68Ga-1 (1 and 2 h after injection), 68Ga-2 (2 and 4 h after injection), and 177Lu-1 and 177Lu-2 (1, 24, 48, and 72 h after injection). The 177Lu-2 biodistribution data were extrapolated for human dosimetry data estimates using OLINDA/EXM 1.1. Therapeutic efficacy of 177Lu-2 was evaluated in mice bearing BxPC-3 tumors.
Results
Peptides 1 and 2 demonstrated high affinity (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Engineering, University of California Davis, Davis, California.
- Division of Hematology/Oncology, Department of Internal Medicine, University of California Davis, Sacramento, California.
- Division of Nuclear Medicine, Department of Radiology, University of California Davis, Sacramento, California; and.
- Department of Biomedical Engineering, University of California Davis, Davis, California; jlsutcliffe@ucdavis.edu.
- Center for Molecular and Genomic Imaging, University of California Davis, Davis, California.
Förderung
- NCI NIH HHS
Zitieren
APA
Ganguly, T., Bauer, N., Davis, R. A., Foster, C. C., Harris, R. E., Hausner, S. H., Roncali, E., Tang, S. Y., & Sutcliffe, J. L. (2023). Preclinical Evaluation of 68 Ga- and 177 Lu-Labeled Integrin α v β 6 -Targeting Radiotheranostic Peptides. Journal of Nuclear Medicine, 64(4), 639-644. https://doi.org/10.2967/jnumed.122.264749
Vancouver
Ganguly T, Bauer N, Davis RA, Foster CC, Harris RE, Hausner SH, et al. Preclinical Evaluation of 68 Ga- and 177 Lu-Labeled Integrin α v β 6 -Targeting Radiotheranostic Peptides. Journal of Nuclear Medicine. 2023;64(4):639-644. doi:10.2967/jnumed.122.264749
BibTeX
@article{Ganguly2023,
author = {Ganguly, Tanushree and Bauer, Nadine and Davis, Ryan A and Foster, Cameron C and Harris, Rebecca E and Hausner, Sven H and Roncali, Emilie and Tang, Sarah Y and Sutcliffe, Julie L},
title = {Preclinical Evaluation of 68 Ga- and 177 Lu-Labeled Integrin α v β 6 -Targeting Radiotheranostic Peptides},
journal = {Journal of Nuclear Medicine},
year = {2023},
volume = {64},
number = {4},
pages = {639--644},
doi = {10.2967/jnumed.122.264749}
}
EUVIMED